References
- Heaney M L, Golde D W. Myelodysplasia. N Engl J Med 1999; 340: 1649–1660
- Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
- Gallagher J C, Bishop C W, Knutson J C, Mazess R B, DeLuca H F. Effects of increasing doses of 1 α-hydroxyvitamin D2 on calcium homeostasis in postmenopausal osteopenic women. J Bone Miner Res 1994; 9: 607–614
- Liu G, Wilding G, Staab M J, Horvath D, Miller K, Dresen A, et al. Phase II study of 1-α-hydroxyvitamin D(2) in the treatment of advanced androgen-indiependent prostate cancer. Clin Cancer Res 2003; 9: 4077–4083
- Cheson B D, Bennett J M, Kantarjian H, Pinto A, Schiffer C A, Nimer S D, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674
- Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1–10
- Nakagawa K, Kurobe M, Ozono K, Konno K, Fujishima T, Takayama H, et al. Novel ring A stereoisomers of 2-methyl-1α,25-dihydroxyvitamin D(3) and 2-methyl-20-epi-1α,25-dihydroxyvitamin D(3): transactivation of target genes and modulation of differentiation in human promyelocytic leukemia (HL-60) cells. Biochem Pharmacol 2000; 59: 691–702
- Bikle D D. 1,25(OH)2D3-modulated calcium induced keratinocyte differentiation. J Investig Dermatol Symp Proc 1996; 1: 22–27
- Ripple G H, Wilding G. Drug development in prostate cancer. Semin Oncol 1999; 26: 217–226
- Mehta R G, Moriarty R M, Mehta R R, Penmasta R, Lazzaro G, Constantinou A, et al. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1α-hydroxyvitamin D5. J Natl Cancer Inst 1997; 89: 212–218
- Motomura S, Kanamori H, Maruta A, Kodama F, Ohkubo T. The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am J Hematol 1991; 38: 67–68
- Slapak C A, Desforges J F, Fogaren T, Miller K B. Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. Am J Hematol 1992; 41: 178–183
- Mellibovsky L, Diez A, Perez-Vila E, Serrano S, Nacher M, Aubia J, et al. Vitamin D treatment in myelodysplastic syndromes. Br J Haematol 1998; 100: 516–520
- Koeffler H P, Aslanian N, O'Kelly J. Vitamin D(2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome. Leuk Res 2005; 29: 1259–1262
- Kumagai T, Shih L Y, Hughes S V, Desmond J C, O'Kelly J, Hewison M, et al. 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res 2005; 15;65: 2488–2497